| dc.contributor.author | Srivastava, Abhishek K. | |
| dc.contributor.author | Yolcu, Esma S. | |
| dc.contributor.author | Dinc, Gunes | |
| dc.contributor.author | Sharma, Rajesh K. | |
| dc.contributor.author | Shirwan, Haval | |
| dc.date.accessioned | 2019-11-24T20:35:12Z | |
| dc.date.available | 2019-11-24T20:35:12Z | |
| dc.date.issued | 2016 | |
| dc.identifier.issn | 2162-402X | |
| dc.identifier.uri | https://dx.doi.org/10.1080/2162402X.2015.1064580 | |
| dc.identifier.uri | https://hdl.handle.net/20.500.12513/1700 | |
| dc.description | WOS: 000373383600041 | en_US |
| dc.description.abstract | Practical experience with cancer vaccines combined with accumulated knowledge of the complex interactions between cancer and immune system rationalize the combinatorial use of immune adjuvants for better efficacy. We recently described a novel adjuvant system based on the costimulatory SA-4-1BBL and TLR4 agonist MPL that has desired therapeutic and safety profiles. | en_US |
| dc.language.iso | eng | en_US |
| dc.publisher | TAYLOR & FRANCIS INC | en_US |
| dc.relation.isversionof | 10.1080/2162402X.2015.1064580 | en_US |
| dc.rights | info:eu-repo/semantics/openAccess | en_US |
| dc.subject | Adjuvant systems | en_US |
| dc.subject | cancer vaccines | en_US |
| dc.subject | CD137 | en_US |
| dc.subject | lung cancer | en_US |
| dc.subject | MPL | en_US |
| dc.subject | SA-4-1BBL | en_US |
| dc.subject | TLR | en_US |
| dc.title | SA-4-1BBL/MPL as a novel immune adjuvant platform to combat cancer | en_US |
| dc.type | other | en_US |
| dc.relation.journal | ONCOIMMUNOLOGY | en_US |
| dc.contributor.department | Kırşehir Ahi Evran Üniversitesi | en_US |
| dc.identifier.volume | 5 | en_US |
| dc.identifier.issue | 1 | en_US |
| dc.relation.publicationcategory | Diğer | en_US |
